Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 155 recruiting now early-phase tilt #25 of 28,707 conditions

Alzheimer Disease: early-phase trial registry

155 of 312 indexed Alzheimer Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #25 of 28,707 conditions by registered trial count.

312 US clinical trials · 155 currently recruiting · #25 of 28,707 conditions by registered trial count

Alzheimer Disease: 312 US clinical trials tracked, 155 recruiting.

Alzheimer Disease is the subject of 312 registered US clinical trials on ClinicalTrials.gov, 155 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 104 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 13 of these trials.

Enrollment posture brief

Registry condition alzheimer-disease

OPEN 155 | RECR 50% | LATE 26 | EARLY 104 | RANK #25 | SPON 13

Nearest open-share peer: PTSD (50% recruiting · 155 trials)

Acute Myeloid Leukemia51.8%Alzheimer Disease (this)50%Cardiovascular Diseases44.1%Multiple Sclerosis37.9%Schizophrenia23.9%
Open-enrollment share among volume-matched conditions near Alzheimer Disease

Alzheimer Disease lists 155 open slots (50% of 312 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Alzheimer Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Alzheimer Disease is recruiting above its size-band peers.

    155 of 312 indexed trials (49.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Alzheimer Disease trials is spread across many organizations.

    Eli Lilly and Company accounts for 13 of 312 trials (4.2%). 178 distinct sponsors appear on at least one study for this condition label.

  3. Typical Alzheimer Disease enrolment sits around 100 participants.

    Median target enrolment is 100 among the 307 trials that report a genuine target (sentinel values excluded). 151 of those (49.2%) plan for fewer than 100 participants.

  4. Alzheimer Disease research is mostly interventional.

    255 interventional and 57 observational studies make up this index (81.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 153Phase 251Phase 318Phase 48

Open and recent trials

312 total, page 7 of 7

COMPLETED NA 6 participants

In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Spanish Language Homes

University of California, Berkeley

NCT05159596

COMPLETED NA 6 participants

Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound

Columbia University

NCT04118764

COMPLETED 4 participants

Feasibility - Infinitome

HealthPartners Institute

NCT04563767

COMPLETED Phase 1 4 participants

Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls

Institute for Neurodegenerative Disorders

NCT01461109

COMPLETED NA 3 participants

Home-based Transcranial Direct Current Stimulation (tDCS) for Behavioral Symptoms in Alzheimer's Disease and Related Dementias (ADRD)

The University of Texas Health Science Center, Houston

NCT05478681

COMPLETED NA 2 participants

Deep Brain Stimulation with LIFUP for Mild Cognitive Impairment and Mild Alzheimer's Disease

University of California, Los Angeles

NCT03347084

COMPLETED 1 participants

Florbetaben PET Imaging in PPA

University of Chicago

NCT04720001

COMPLETED Phase 4

The Depression in Alzheimer's Disease Study (DIADS)

Johns Hopkins University

NCT00009191

COMPLETED Phase 3

Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

Otsuka Pharmaceutical Development & Commercialization

NCT00041678

COMPLETED Phase 3

Serotonergic Pharmacotherapy for Agitation of Dementia

Bruce Pollock

NCT00009204

COMPLETED Phase 2

A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)

National Institute on Aging (NIA)

NCT00004845

COMPLETED Phase 3

Evaluation of Galantamine in the Treatment of Alzheimer's Disease

Janssen

NCT00000172

← Previous Page 7 of 7

Phase Distribution

PhaseTrial count
Phase 1 53
Phase 2 51
Phase 3 18
Phase 4 8

Named interventions

Most-linked intervention names on Alzheimer Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
37 trials
11C-ER176 Drug
5 trials
Donanemab Drug
4 trials
GENUS device (Active Settings) Device
3 trials
Florbetaben Drug
3 trials
Dementia Guide Expert Behavioral
3 trials
Brain CareNotes Behavioral
3 trials
Placebo Other
3 trials

US sites by state

Facility locations filed on Alzheimer Disease trials. A trial with sites in several states counts in each.

California 75 trials
Florida 63 trials
Massachusetts 40 trials
New York 37 trials
Arizona 36 trials
Missouri 27 trials
Texas 26 trials
Georgia 22 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Alzheimer Disease page

312 registered trials, 155 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alzheimer Disease condition card totals 312 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.